BINDING OF [H-3] SR-49059, A POTENT NONPEPTIDE VASOPRESSIN V-1A ANTAGONIST, TO RAT AND HUMAN LIVER MEMBRANES

被引:38
作者
SERRADEILLEGAL, C
RAUFASTE, D
MARTY, E
GARCIA, C
MAFFRAND, JP
LEFUR, G
机构
[1] Sanofi Rech, F 31036 Toulouse
关键词
D O I
10.1006/bbrc.1994.1236
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The new potent and selective nonpeptide vasopressin V-1a antagonist, SR 49059, was tritiated and used for the characterization of rat and human liver AVP V-1a receptors. Binding of [H-3] SR 49059 was time-dependent, reversible and saturable. A single class of high affinity binding sites was identified with K-d values of 0.63 +/- 0.13 and 2.95 +/- 0.64 nM, in rat and human liver membranes, respectively. The maximal binding capacity (B-MAX) was about 7 times higher in rat than in human liver preparations. The relative potencies of several AVP/oxytocin agonists or antagonists to inhibit [H-3] SR 49059 binding confirmed that this ligand labeled a homogenous population of sites with the expected AVP V-1a profile. Furthermore, [H-3] SR 49059 or unlabeled SR 49059 displayed only slight species differences between rat and human V-1a receptors, whereas OPC-21268, another nonpeptide V-1a antagonist, exhibited a high species-related potency with more than 500 fold higher affinity for rat than for human liver V-1a receptors. Thus, [H-3] SR 49059 is the first nonpeptide AVP V-1a ligand reported having highly specific activity, stability, specificity and affinity. This makes it a suitable probe for labeling AVP V-1a receptors in rat and also in human tissues. (C) 1994 Academic Press, Inc.
引用
收藏
页码:353 / 360
页数:8
相关论文
共 18 条
[1]   MOLECULAR-CLONING OF THE RECEPTOR FOR HUMAN ANTIDIURETIC-HORMONE [J].
BIRNBAUMER, M ;
SEIBOLD, A ;
GILBERT, S ;
ISHIDO, M ;
BARBERIS, C ;
ANTARAMIAN, A ;
BRABET, P ;
ROSENTHAL, W .
NATURE, 1992, 357 (6376) :333-335
[2]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[3]   DIRECT IDENTIFICATION OF THE RAT HEPATOCYTE ARGININE-8 VASOPRESSIN RECEPTOR WITH A RADIOLABELED V1-SELECTIVE ANTAGONIST [J].
CORNETT, LE ;
CATE, CM .
JOURNAL OF RECEPTOR RESEARCH, 1989, 9 (01) :1-18
[4]  
GAL S, 1993, J CLIN INVEST, V93, P224
[5]   KINETIC AND PHARMACOLOGICAL CHARACTERIZATION OF VASOPRESSIN MEMBRANE-RECEPTORS FROM HUMAN-KIDNEY MEDULLA - RELATION TO ADENYLATE-CYCLASE ACTIVATION [J].
GUILLON, G ;
BUTLEN, D ;
CANTAU, B ;
BARTH, T ;
JARD, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 85 (3-4) :291-304
[6]   CHARACTERIZATION OF THE HUMAN LIVER VASOPRESSIN RECEPTOR - PROFOUND DIFFERENCES BETWEEN HUMAN AND RAT VASOPRESSIN-RECEPTOR-MEDIATED RESPONSES SUGGEST ONLY A MINOR ROLE FOR VASOPRESSIN IN REGULATING HUMAN HEPATIC-FUNCTION [J].
HOWL, J ;
ISMAIL, T ;
STRAIN, AJ ;
KIRK, CJ ;
ANDERSON, D ;
WHEATLEY, M .
BIOCHEMICAL JOURNAL, 1991, 276 :189-195
[7]  
Jard S, 1987, Adv Nephrol Necker Hosp, V16, P1
[8]  
LASZLO FA, 1991, PHARMACOL REV, V43, P73
[9]   CLONING AND CHARACTERIZATION OF A VASOPRESSIN V2 RECEPTOR AND POSSIBLE LINK TO NEPHROGENIC DIABETES-INSIPIDUS [J].
LOLAIT, SJ ;
OCARROLL, AM ;
MCBRIDE, OW ;
KONIG, M ;
MOREL, A ;
BROWNSTEIN, MJ .
NATURE, 1992, 357 (6376) :336-339
[10]  
MAH S C, 1987, Drugs of the Future, V12, P1055